ClinicalTrials.gg
Not yet recruitingNCT07569991CBT+Updated Sep 3, 2026

Digitally Enhanced Cognitive-Behavioral Therapy

An interventional study of Cognitive-behavioral therapy (CBT) and Digital app in Depression in Adolescence, Obesity & Overweight and Cognitive-behavioral Therapy, sponsored by Colorado State University. Not yet recruiting at 1 site in United States. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-09-03.

Sponsored by Colorado State University · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
12 Years to 17 Years
Sex
All
01

Study summary

Adolescent depression is a major public health problem. Depression affects adolescents' emotional well-being now and in the future, and it also affects their physical health, especially the risk for heart disease and other cardiovascular and metabolic health problems. In adolescents with depression and obesity, evidence-based programs for depression, like cognitive-behavioral therapy (CBT), might improve physical health, in part by supporting healthy behaviors such as physical activity, nutritious eating, and getting enough sleep. Our preliminary studies provide support for this overarching hypothesis. If adolescents have access to a digital app to support practicing CBT skills in between program sessions, it might especially help them to learn skills that help to feel better and be healthier in their day-to-day lives. We are tailoring a digital app for this purpose and we will make changes to the app based on feedback from adolescents, their parents, and their doctors. Once the app is well-liked and helpful, and works well as a support for taking part in CBT, we will randomly assign 60 adolescents with depression and overweight/obesity to either "CBT+" - a CBT group program plus the app, or "CBT-only" - the CBT group program only. We will pilot test whether this research is feasible, likeable, and credible, learning information that will inform a larger study to test of CBT+ can support emotional well-being, health behavior, and cardiovascular and metabolic health in adolescents.

Read the detailed description

Adolescent depression is a major public health problem that has serious consequences for cardiometabolic disease, predicting heightened risk for glucose dysregulation, type 2 diabetes onset, and cardiovascular events. Evidence-based interventions such as cognitive-behavioral therapy (CBT) to decrease depression in adolescents with elevated body mass index (BMI ≥85th percentile for age and sex) are anticipated to improve cardiometabolic health, in part by ameliorating the negative impacts of depression on health behavior (e.g., physical activity, eating, and sleep). Our preliminary studies provide support for this overarching hypothesis. However, effect sizes for CBT were small-to-moderate, possibly due to less-than-optimal home practice in between sessions. Homework completion tracks with treatment effects in our team's and others' studies, likely because homework facilitates skills acquisition in daily life. Our overarching study rationale is that enhancement of CBT-group with a digital app is likely to strengthen homework completion and translation of CBT skills to healthier coping and behavior, leading to stronger improvements in cardiometabolic health than CBT-group alone. We will leverage mobile health (mHealth) to adapt a CBT-digital app for the distinct needs and preferences of adolescents with depression and elevated BMI. After we optimize the app's integration with CBT-group virtual sessions through focus groups and iterative pilot testing with adolescents, we will conduct a two-arm, single-site pilot and feasibility randomized controlled trial to compare a digitally-enhanced CBT-group (CBT+) with a virtual CBT-group only in 60 adolescents with depression and overweight/obesity to assess feasibility, acceptability, proof-of-concept, and implementation outcomes.

02

Conditions studied

  • Depression in Adolescence
  • Obesity & Overweight
  • Cognitive-behavioral Therapy
  • Mobile Health Technology (mHealth)
  • Health Behavior

Keywords

  • cognitive-behavioral therapy
  • depression
  • adolescents
  • cardiometabolic health
  • mHealth
03

In context

Obesity

11,522 studies on the registry are indexed under Obesity; 2,033 are open to participants now.

This study's planned enrollment of 60 is below the median of 67 across 9,006 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Colorado State University is the lead sponsor of 117 studies on the registry; 19 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 12-17 years
  • (BMI) ≥85th percentile for age and sex
  • Elevated depression symptoms, Center for Epidemiologic Studies-Depression Scale (CES-D) ≥21

Exclusion criteria

Exclusion Criteria:

  • Type 2 diabetes; Fasting glucose ≥126 mg/dL or ≥6.5
  • Major developmental (e.g., intellectual developmental disability) or medical or genetic condition (e.g. cancer, Bardet-Biedhl)
  • Pregnancy/breastfeeding (females)
  • Bariatric surgery, weight loss medication, or weight loss >3% in the past 3 months
  • Active suicidality or self-harm
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Cognitive-behavioral therapy (CBT)

    Six-week, six-session group cognitive-behavioral therapy (CBT) delivered virtually; CBT focuses on changing thoughts and changing behaviors to improve mood

    Behavioral: Cognitive-behavioral therapy (CBT)

  • Experimental
    Cognitive-behavioral therapy-Plus (CBT+)

    Six-week, six-session group cognitive-behavioral therapy (CBT) delivered virtually; CBT focuses on changing thoughts and changing behaviors to improve mood PLUS access to a digital app to use throughout the CBT group program

    Behavioral: Cognitive-behavioral therapy (CBT) · Behavioral: Digital app

Interventions

  • BehavioralCognitive-behavioral therapy (CBT)

    Six-week, six-session group cognitive-behavioral therapy (CBT) delivered virtually

  • BehavioralDigital app

    App tailored to support cognitive-behavioral therapy (CBT) skills and homework practices

06

What researchers measure

Primary outcomes

  1. Intervention Acceptability

    ≥80% of adolescents will report likeability/benefit (≥4 on 1-5 scale where 5=Extremely)

    Time frame: Six-week follow-up

  2. Intervention Feasibility

    ≥80% of adolescents will receive 80% group dosage (≥5 of 6 sessions)

    Time frame: Six-week follow-up

  3. App Acceptability

    Of those in CBT+, ≥80% of adolescents will use the app regularly (≥3 times per week)

    Time frame: Six-week follow-up

Secondary outcomes

  1. Enrollment Feasibility

    10 teens in ≤12 weeks to form CBT+ vs. CBT-group only parallel cohorts

    Time frame: End-of-enrollment

  2. Enrollment Feasibility

    ≥75% of those determined to be eligible will enroll

    Time frame: End-of-enrollment

  3. Protocol Feasibility

    \<10% missing data

    Time frame: End-of-3-month follow-ups

  4. Protocol Feasibility

    ≥80% 3-month follow-up retention

    Time frame: End-of-3-month follow-ups

Other outcomes

  1. Depression Symptoms

    Adolescent report on the 20-item Center for Epidemiologic Studies-Depression Scale (CES-D), total score

    Time frame: Six-week follow-up and 3-month follow-up

  2. Negative Automatic Thoughts

    Adolescent report on the Negative Automatic Thoughts subscale of the Children's Automatic Thoughts Scale-Negative/Positive

    Time frame: Six-week follow-up and 3-month follow-up

  3. Pleasant Activities

    Adolescent report of frequency/pleasantness of pleasant activities on the Pleasant Events Schedule

    Time frame: Six-week follow-up and 3-month follow-up

  4. Homework Completion

    Adolescent report on the Homework Rating Scale-Version 2

    Time frame: Six-week follow-up

  5. Coping

    Adolescent report on the Brief COPE inventory

    Time frame: Six-week follow-up and 3-month follow-up

  6. Self-efficacy

    Adolescent report on the Self-efficacy Questionnaire for Children

    Time frame: Six-week follow-up and 3-month follow-up

  7. Loneliness

    Adolescent report on the UCLA Loneliness Scale

    Time frame: Six-week follow-up and 3-month follow-up

  8. Physical Activity

    Time spent in moderate-to-vigorous physical activity measured from the adolescent-worn actigraphy

    Time frame: Six-week follow-up and 3-month follow-up

  9. Sedentary Time

    Time spent sedentary measured from adolescent-worn actigraphy

    Time frame: Six-week follow-up and 3-month follow-up

  10. Emotional Eating

    Adolescent report on the Emotional Eating Scale-Adapted for Children and Adolescents

    Time frame: Six-week follow-up and 3-month follow-up

  11. Loss-of-control Eating

    Adolescent report of loss-of-control episodes on the Loss-of-Control Eating Disorder Questionnaire for Children

    Time frame: Six-week follow-up and 3-month follow-up

  12. Insulin Resistance

    Homeostatic model assessment of insulin resistance derived from adolescent fasting insulin and fasting glucose

    Time frame: Six-week follow-up and 3-month follow-up

  13. Blood pressure

    Systolic blood pressure derived from adolescent ambulatory monitoring

    Time frame: Six-week follow-up and 3-month follow-up

  14. Blood Pressure

    Diastolic blood pressure derived from adolescent ambulatory monitoring

    Time frame: Six-week follow-up and 3-month follow-up

  15. Lipids

    Adolescent triglycerides

    Time frame: Six-week follow-up and 3-month follow-up

  16. Lipids

    Adolescent HDL cholesterol

    Time frame: Six-week follow-up and 3-month follow-up

  17. Lipids

    Adolescent LDL cholesterol

    Time frame: Six-week follow-up and 3-month follow-up

  18. Glycemic Variability

    Standard deviation of glucose derived from adolescent wear of continuous glucose monitor

    Time frame: Six-week follow-up and 3-month follow-up

07

Study locations

1 site
08

References and documents

Publications

  • Shomaker LB, Kelly NR, Pickworth CK, Cassidy OL, Radin RM, Shank LM, Vannucci A, Thompson KA, Armaiz-Flores SA, Brady SM, Demidowich AP, Galescu OA, Courville AB, Olsen C, Chen KY, Stice E, Tanofsky-Kraff M, Yanovski JA. A Randomized Controlled Trial to Prevent Depression and Ameliorate Insulin Resistance in Adolescent Girls at Risk for Type 2 Diabetes. Ann Behav Med. 2016 Oct;50(5):762-774. doi: 10.1007/s12160-016-9801-0. PubMed 27333897 ↗
  • Perzow SED, Hu J, Bristol M, Ruzicka EB, Clementi MA, Handing EP, Vargas E, Gutierrez-Colina AM, Gulley LD, Shomaker LB. Systematic review and meta-analysis of psychological interventions for depression symptoms in young people with long-term physical health conditions. J Pediatr Psychol. 2025 Jul 1;50(7):699-714. doi: 10.1093/jpepsy/jsaf049. PubMed 40795045 ↗
  • Shomaker LB, Kelly NR, Radin RM, Cassidy OL, Shank LM, Brady SM, Demidowich AP, Olsen CH, Chen KY, Stice E, Tanofsky-Kraff M, Yanovski JA. Prevention of insulin resistance in adolescents at risk for type 2 diabetes with depressive symptoms: 1-year follow-up of a randomized trial. Depress Anxiety. 2017 Oct;34(10):866-876. doi: 10.1002/da.22617. Epub 2017 Mar 31. PubMed 28370947 ↗

Individual participant data

Plan to share: Yes — CBT-app usage and CBT group attendance; adolescent depression questionnaire data; CBT and CBT-app adolescent questionnaires assessing CBT-group and CBT-app therapeutic targets (thoughts, pleasant activities, coping, self-efficacy, loneliness); health behavior measured by actigraphy (physical activity/sleep) and adolescent questionnaire (eating); adolescent cardiometabolic health indicators by fasting blood draw to assess lipids (triglycerides, cholesterol) and glucose/insulin to calculate insulin resistance, continuous glucose monitoring data, and heart rate/blood pressure

Supporting information: Study protocol, Informed consent form

Time frame: Data will be made available no later than the time of an associated publication

Access criteria: We will use the openICPSR data repository, an NIH-approved self-publishing repository for social, behavioral, and health sciences research data; to request access of the data, researchers will follow the standard process at openICPSR

Data sharing details ↗ · www.openicpsr.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Jan 2028, 12 months later.

Of 3,680 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 12 months is below that.

Counting every sponsor, half of 3,843 studies reached it within 22 months; a quarter within 10 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2026
First posted
May 6, 2026
StartEst.
Jan 1, 2027
Primary completionEst.
Jan 1, 2028
CompletionEst.
Aug 1, 2028
Last update
Sep 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07569991
Responsible party
Sponsor
First posted
May 6, 2026
Start date
Jan 1, 2027 (estimated)
Primary completion
Jan 1, 2028 (estimated)
Completion
Aug 1, 2028 (estimated)
Last update
Sep 3, 2026

Study contacts

Lauren B Shomaker, PhD
Contact
lauren.shomaker@colostate.edu
970-491-3217

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion